Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder

Launched by BATMAN UNIVERSITY · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of two treatments—platelet-rich plasma (PRP) and autologous conditioned serum (ACS)—to help people with temporomandibular joint (TMJ) osteoarthritis, a common source of chronic pain. TMJ disorders can make it hard to open your mouth or move your jaw comfortably. The trial is looking for adults over 18 who have tried other treatments without success and have been diagnosed with TMJ osteoarthritis. However, those who have had recent injuries or surgeries to their jaw, certain growth disorders, systemic inflammatory diseases, or who are pregnant or breastfeeding cannot participate.

Participants in the trial will receive either PRP or ACS, both of which are made from their own blood, to see which treatment works better for relieving their symptoms. The study is currently recruiting volunteers, and participants can expect close monitoring and care throughout the process. This trial aims to improve patient outcomes and provide better treatment options for those suffering from TMJ disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Over 18 years old
• • Previously received conservative treatment but no improvement in symptoms
• • Patients with TMJ osteoarthritis
• Exclusion Criteria:
• • Patients who have experienced TMJ trauma or have undergone surgical procedures in this region will be excluded from the study.
• • Patients with facial growth disorders, systemic inflammatory joint diseases, condylar pathologies, or signs of myalgia
• • Patients who are pregnant or in the lactation period